Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

DZ Bank Adjusts Price Target on Regeneron Pharmaceuticals

Nov 5, 2026, 11:34 AM UTC · Primary ticker $REGN

DZ Bank has increased its price target for Regeneron Pharmaceuticals from $900 to $1,067, indicating a more optimistic valuation outlook from the firm. This adjustment is a positive signal for investors, reflecting an analyst's updated assessment of the company's future prospects.

DZ Bank has revised its price target for Regeneron Pharmaceuticals (REGN) upwards from $900 to $1,067. This change signifies a more favorable valuation perspective from the analyst firm, likely driven by updated financial models or recent company developments not explicitly detailed in the filing. For traders, this represents a positive sentiment indicator, potentially leading to short-term upward price momentum as investors react to the increased target. While not a fundamental change in the company's operations, an analyst upgrade can influence market perception and investor confidence, offering a short-term opportunity for those bullish on REGN. The long-term implications depend on whether the underlying reasons for the target increase translate into actual business performance.

$REGN positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.